We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
630
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- Sun Pharma voluntarily recalled a single batch of 675 vials of Doxorubicin Hydrochloride Liposome Injection after detecting glass particles during production. - The FDA warns that glass particles administered intravenously pose serious safety risks including blood vessel blockage and life-threatening blood clot events. - The recalled cancer treatment drug is used for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma with an expiration date of May 31, 2027. - No adverse incidents have been reported to date, and Sun Pharma is arranging product returns and replacements through express overnight mail.
